Beverly Davidson

Siren Biotechnology Launches to Pioneer Universal AAV Immuno-Gene Therapy™ for Cancer

Retrieved on: 
Wednesday, May 17, 2023
Lux Capital, San Francisco, Spark Therapeutics, Beverly Davidson, University, Therapy, University of California, San Francisco, Sutro Biopharma, Cancer, Eric Schmidt, Toxicity, MBA, Civilization, Immunotherapy, Doctor of Philosophy, AAV, Washington University in St. Louis, Founders Fund, Brain, UCSF, Salk Institute for Biological Studies, Engineering, Coronavirus Scientific Advisory Board, Immune system, Annual general meeting, Initial public offering, Neoplasm, Cytokine, Universal, Universal design, Medical imaging, Vaccine, Pharmaceutical industry, Siren

The company’s name was inspired by the powerful signal Universal AAV Immuno-Gene Therapy sends to the immune system, stimulating an immediate and comprehensive anti-tumor response.

Key Points: 
  • The company’s name was inspired by the powerful signal Universal AAV Immuno-Gene Therapy sends to the immune system, stimulating an immediate and comprehensive anti-tumor response.
  • “The world needs big, bold, new ideas to fight cancer, and Universal AAV Immuno-Gene Therapy is exactly that.
  • Our design and engineering of this modality redefines both AAV gene therapy and cytokine immunotherapy, and in doing so, changes the game for cancer treatment,” said Nicole Paulk, PhD, Founder and Chief Executive Officer of Siren.
  • “This is the first AAV gene therapy for cancer and the first AAV gene therapy that is universal, meaning we can make it once and use it for numerous indications.

Carbon Biosciences Launches with $38 Million Series A Financing to Advance Novel Gene Therapy Platform and Pipeline

Retrieved on: 
Tuesday, June 21, 2022
Research, Finance, Genetics, Clinical Trials, Professional Services, Biotechnology, Health, Other Science, Science, Yan, Beverly Davidson, Partner, MBBS, University, Director, LinkedIn, Pressure, CFTR, Vertex, Inflammation, National Institute of Dental and Craniofacial Research, Therapy, Company, University College London, Tissue, AAV, Technology, CEO, University of Iowa, MRCP, Founder, Lung, Alnylam Pharmaceuticals, Board, University of Kansas, Parvoviridae, Industry, Tropism, UCL Great Ormond Street Institute of Child Health, Chairperson, FRCP, List of life sciences, Lists of diseases, Patient, Multimedia, Cystic fibrosis, Senior, CBO, Cystic Fibrosis Foundation, Gene, Research, Program, Infection, Doctor of Philosophy, UCL, Center, Roy J. and Lucille A. Carver College of Medicine, Pharmaceutical industry, Management, Pediatric nursing, Photis Kontoglou, Molecular medicine, Engelhardt, Microbiology

Carbon Biosciences (Carbon), a Longwood Fund founded biotech company and emerging leader in the development of novel parvovirus-derived gene therapies, today announced a $38 million Series A financing led by Agent Capital.

Key Points: 
  • Carbon Biosciences (Carbon), a Longwood Fund founded biotech company and emerging leader in the development of novel parvovirus-derived gene therapies, today announced a $38 million Series A financing led by Agent Capital.
  • Carbon is harnessing novel parvovirus vectors that can deliver larger gene therapy payloads with enhanced tissue specificity and with minimal neutralizing immunity.
  • Carbons technology will enable a diversified pipeline with potential applications across the wide range of tissues impacted in many unaddressed diseases.
  • Carbons scientific co-founders and scientific advisory board members are among the most experienced thought leaders in the gene therapy field.